CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Camrelizumab , apatinib and chemotherapydrug
Likely dose
Camrelizumab , apatinib and chemotherapy 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04625803
NCT04625803Phase 2Completed

Camrelizumab and Apatinib Combined With Chemotherapy (mFOLFOX6) in Neoadjuvant Therapy for Locally Advanced Colon Cancer

Zhejiang University·interventional·Posted Nov 12, 2020·Updated Jun 17, 2025

In Brief

A Phase 2 clinical trial evaluating Camrelizumab , apatinib and chemotherapy for Colon Cancer and Neoadjuvant Therapy. Completed, enrolled 64 participants across 1 site.

Detailed Summary

To determine the Efficacy and Safety of camrelizumab and apatinib combined with chemotherapy (mFOLFOX6) for MSS/pMMR locally advanced colon cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 12, 2020
Enrollment StartJan 4, 2021
Primary CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.6 years ago

Interventions

Camrelizumab , apatinib and chemotherapydrug

Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle Apatinib 250mg oral administration once a day, for two months mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate.